C-A Complex Spike Antigen for SARS-CoV-2 Variant Cross-Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent need for effective vaccines and therapies to combat SARS-CoV-2 infections, particularly against emerging strains, as current vaccines show reduced efficacy against variants like alpha, beta, gamma, and delta, and there are no therapeutics available to address the global spread and high fatality rates of the virus.
Innovation Solution
Development of an immunogenic composition comprising a nucleic acid molecule encoding a peptide sequence that mimics the intermediate structure of the SARS-CoV-2 spike protein and ACE2 receptor complex (C-A Complex), which elicits both humoral and cellular immune responses, including neutralizing antibodies and CD8+ T cell responses, and can be administered with adjuvants for enhanced immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current vaccines are used against SARS-CoV-2, then initial protection is achieved, but efficacy is reduced against emerging variants
Solution Approach 1:
The patent designs a universal vaccine candidate comprising a chimeric spike protein that combines conserved regions from multiple coronavirus strains (SARS-CoV, SARS-CoV-2, and other CoVs). This chimeric construct is intended to elicit broad-spectrum neutralizing antibodies that can recognize and neutralize multiple variants and strains simultaneously, achieving cross-protection without requiring strain-specific vaccines for each emerging variant.
Solution Approach 2:
The patent modifies the spike protein structure by creating a chimeric construct with specific amino acid sequences from different coronavirus strains. The vaccine candidate incorporates conserved epitopes and receptor-binding domains that are preserved across variants, while removing or modifying variable regions that drive strain-specific immunity. This parameter change in protein sequence composition enables the vaccine to maintain efficacy across diverse SARS-CoV-2 variants.
2Speed
If traditional vaccine platforms are used, then development is straightforward, but response time to emerging strains is slow
Solution Approach 1:
The patent employs a pre-designed chimeric spike protein platform that incorporates conserved regions from multiple coronavirus strains before any specific outbreak occurs. This preliminary construction of a universal vaccine candidate allows for rapid deployment and adaptation when new strains emerge, as the basic vaccine architecture is already in place and can be quickly adjusted by modifying specific protein regions rather than developing from scratch.
Solution Approach 2:
The patent uses molecular modeling and computational biology to create a virtual copy of the chimeric spike protein structure that can be rapidly synthesized and tested. This digital replica allows for quick validation of vaccine candidates and rapid scaling of production, significantly reducing the time required to transition from design to deployment compared to traditional experimental approaches.
3Adaptability or versatility
If broad-spectrum vaccines are developed, then protection against multiple variants is achieved, but manufacturing complexity increases
Solution Approach 1:
The patent divides the coronavirus spike protein into distinct functional segments: conserved regions that provide universal recognition, variable regions that differ between strains, and linker regions that maintain structural integrity. The chimeric construct is designed to incorporate only the essential conserved segments needed for broad-spectrum protection, while excluding or simplifying the variable regions. This segmentation allows for streamlined manufacturing by focusing production on the conserved, strain-independent portions of the protein.
Solution Approach 2:
The patent applies different protein sequences and structural features to different regions of the chimeric spike protein based on their functional requirements. The receptor-binding domain uses conserved sequences from multiple strains to ensure broad recognition, while the S2 fusion domain uses sequences optimized for structural stability and manufacturability. This localized optimization allows the vaccine to achieve broad-spectrum protection through the RBD while maintaining ease of manufacture through simplified S2 region design.
Data Source
AI summary
Provided herein is an immunogenic composition comprising a synthetic antigen to COVID spike proteins, particularly the chimeric intermediate structure C-A Complex. Also disclosed herein is a method of preventing and/or treating a COVID infection in a subject in need thereof, by administering the immunogenic composition to the subject.